Date: 2015-09-29
Type of information: Series B financing round
Company: Corvus Pharmaceuticals (USA - CA)
Investors: Rock Springs Capital Management (USA - MD) Fidelity Management and Research Company (USA - MA) Blackrock (USA) accounts managed by T. Rowe Price, Jennison Associates (USA - NY) Roche Venture Fund (Switzerland) Cormorant Asset Management (USA - MA) Sphera Funds Management (Israel) venBio (USA - CA), Cowen Private Investments (USA - NY) OrbiMed (USA - NY) Adams Street Partners (USA) Novo Ventures (Denmark)
Amount: $75 million (€ 66.8 million)
Funding type: series B financing round
Planned used: Corvus Pharmaceuticals is focused on the development of novel agents targeting the immune system to treat patients with cancer. The proceeds will be used to expand the company’s research and development programs of multiple small molecule and antibody agents in immuno-oncology, including the initiation of a multicenter Phase 1B trial, which is expected to begin in the first quarter of 2016.
Others: * On September 29, 2015, Corvus Pharmaceuticals, a private clinical-stage biopharmaceutical company focused on the development of novel agents targeting the immune system to treat patients with cancer, announced that it closed a $75 million Series B financing. The transaction was led by Rock Springs Capital Management and included other leading healthcare investors such as Fidelity Management and Research Company, Blackrock, funds, accounts managed by T. Rowe Price, Jennison Associates (on behalf of certain clients), Roche Venture Fund, Cormorant Asset Management, Sphera Funds Management, venBio Select and Cowen Private Investments. Founding investors, Orbimed, Novo Ventures and Adams Street Partners also participated in the transaction. Cowen and Company served as an advisor to Corvus.
Therapeutic area: Cancer - Oncology
